Lineage Cell Therapeutics (LCTX) Change in Accured Expenses (2010 - 2026)

Lineage Cell Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 1529.52% year-over-year to -$1.7 million; the trailing twelve-month figure through Mar 2026 stood at $665000.0 (up 154.87% YoY), and the FY2025 full-year result was $2.3 million, up 235.1% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.7 million, down from $2.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.5 million in Q4 2025, with the low at -$18.9 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$1.3 million across 5 years, with a median of -$354000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 1733.66% — and 2025, when it soared 2435.05%.
• Lineage Cell Therapeutics' Change in Accured Expenses stood at -$1.1 million in 2022, then surged by 202.83% to $1.2 million in 2023, then plunged by 91.65% to $97000.0 in 2024, then soared by 2435.05% to $2.5 million in 2025, then sank by 169.58% to -$1.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.7 million (Q1 2026), $2.5 million (Q4 2025), and $271000.0 (Q3 2025), per Business Quant data.